Trials / Conditions / Refractory Anemia With Ringed Sideroblasts

Refractory Anemia With Ringed Sideroblasts

15 registered clinical trials studyying Refractory Anemia With Ringed Sideroblasts.

Status	Trial	Sponsor	Phase
Completed	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255	National Cancer Institute (NCI)	Phase 2
Completed	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome NCT01165996	Case Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT NCT01012492	Boston Children's Hospital	Phase 2
Completed	Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01146210	Children's Oncology Group	—
Completed	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605	National Cancer Institute (NCI)	Phase 2
Completed	Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes NCT00104962	National Cancer Institute (NCI)	Phase 1
Completed	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Terminated	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Trans NCT00119366	Fred Hutchinson Cancer Center	Phase 2
Completed	Tipifarnib in Treating Patients With Myelodysplastic Syndromes NCT00005845	National Cancer Institute (NCI)	Phase 1
Completed	Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Thalidomide in Treating Patients With Myelodysplastic Syndrome NCT00015990	National Cancer Institute (NCI)	Phase 2
Completed	Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer NCT00012376	National Cancer Institute (NCI)	Phase 1
Completed	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177	Fred Hutchinson Cancer Center	Phase 1
Completed	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogeno NCT00002798	National Cancer Institute (NCI)	Phase 3